Drug General Information
Drug ID	D0A8FD
Former ID	DIB016746
Drug Name	S-18327
Indication	Psychotic disorders [ICD9: 290-299; ICD10:F20-F29]		Discontinued in Phase 1	[546690]
Company	Servier
Structure		Download 2D MOL 3D MOL
Canonical SMILES	C1(=O)N(CCN1CCN1CCC(c2noc3c2ccc(c3)F)CC1)c1ccccc1
CAS Number	CAS 200398-40-9
Target and Pathway
Target(s)	D(2) dopamine receptor	Target Info	Modulator	[525657]
KEGG Pathway	Rap1 signaling pathway
	cAMP signaling pathway
	Neuroactive ligand-receptor interaction
	Gap junction
	Dopaminergic synapse
	Parkinson's disease
	Cocaine addiction
	Alcoholism
PANTHER Pathway	Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
	Dopamine receptor mediated signaling pathway
	Nicotine pharmacodynamics pathway
Reactome	Dopamine receptors
	G alpha (i) signalling events
WikiPathways	Hypothetical Network for Drug Addiction
	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	Genes and (Common) Pathways Underlying Drug Addiction
	GPCR ligand binding
	GPCR downstream signaling
	Nicotine Activity on Dopaminergic Neurons
References
Ref 546690	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009651)
Ref 525657	S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. J Pharmacol Exp Ther. 2000 Jan;292(1):38-53.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.